SV Health Investors, formerly SV Life Sciences, is a leading healthcare and life sciences venture capital and growth equity firm. We have a solid track record of delivering strategic, practical and impactful support to our portfolio companies. April 13, 2017 By Alex Keown, BioSpace.com Breaking News Staff BOSTON, Mass. SV Health Investors (‘SV’) is a leading international life sciences venture capital firm. SV targets growth equity investments in healthcare services and digital health; early-stage and revenue-stage opportunities in medical devices; and early-stage opportunities in biotechnology. SV Design designed the four-story, 15,000 square-foot expansion of the Ginger Judge Science Center at Endicott College to accommodate growth in the science, technology, engineering, and mathematics department. Mr. LaViolette joined SVLS in early 2009 as Venture Partner. Their goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments. Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. SV has a 25-year track record in the US and Europe with offices in Boston and London. The team at SV Life Sciences is driving innovation across the medical devices industry with over $2.7 billion in capital under management in seven private healthcare funds and one publicly listed fund. SV Health Investors, formerly named SV Life Sciences, is a healthcare and life sciences venture capital and growth equity firm. our portfolio. We can assist you in your drive for excellence with learning development systems and training content trusted by the FDA for the healthcare and life sciences … Portfolio Highlights: Direct Flow Medical, CardioFocus, Endotronix. Cancer Research UK forms partnership with SV Health Investors in life sciences investment fund to accelerate development of cancer medicines Our complete portfolio of services includes combination product usability studies and packaging sterility, shelf life and transportation validation. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). We focus on two therapeutic areas – Haematology and Immunology – and also have a portfolio of Specialty Care products. Honeywell Boosts AI Life Sciences Portfolio With $1.3 Billion Sparta Systems Buy Forbes - Maribel Lopez. SV Health Investors, formerly named SV Life Sciences, is a healthcare and life sciences venture capital and growth equity firm. Sobi is an international biopharmaceutical company focused on rare diseases. This was recognised in the UK Life Sciences Strategy and this new fund, in partnership with SV, will be a huge boost to advancing cancer research here in the UK. SV Health Investors is a hedge fund with 16 clients and discretionary assets under management (AUM) of $1,436,405,958 (Form ADV from 2020-03-30). "Since joining SVLS, Paul has successfully applied his tremendous experience with large-scale medical technology businesses to our portfolio of development stage companies," … SV Health Investors, LLC has disclosed 10 total holdings in their latest SEC filings. Currently, Bob is CEO of ev3, and serves on the Board of Directors of SVLSF IV portfolio companies iTherapeutix and LenSx Lasers. Prior to SV Life Sciences, Darren was Cofounder and President of two companies—ClinCare and PharmaStar. Prior to joining Polar Capital, for five years David was portfolio manager of the International Biotechnology Trust at SV Life Sciences. Mark Lambrecht Director, Global Health & Life Sciences Practice Belgium-Based "Analytics, AI and digital options hold tremendous power and potential for the future of health care and life sciences. We build next generation technologies serving the Life Sciences, Defense and Space, and Financial industry sectors. Previously, he was a healthcare consultant for Accenture. He has over 20 years’ investment experience in the healthcare sector. Business Growth Fund's portfolio represents the diverse talents of UK and Irish businesses today, across every region and sector of the economy. SV Life Sciences, a life sciences-based venture capital firm, has added to new partners to its Boston office. Boston venture capital firm SV Life Sciences has changed its name to SV Health Investors and closed on a $400 million fund, bringing its total under management to around $2 billion. My whole career in biotech and technology has involved applying science and analytics to research genomes, modernize clinical trials and improve patient outcomes. General Atlantic Portfolio. Darren holds an AB in government from Harvard College and an MBA from the Wharton School … We know that continuous experimentation, and a sense of adventure, can light the creative fires that forge the best innovation. David joined Polar Capital in August 2013 as a Fund Manager within the healthcare team. Akouos is building the leading gene therapy company focused on hearing disorders. – Venture capital firm SV Life Sciences has changed its name to SV Health Investors.The company also closed its sixth flagship fund with $400 million. Addition Increased Space for College's Life Science Program. Capital Com SV Investments Limited, company Registration Number: 354252, registered address: 28 Octovriou 237, Lophitis Business Center II, 6th floor, 3035, Limassol, Cyprus. “Ximedica is a unique growth platform in medtech and a great addition to the SV Life Sciences portfolio. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building on a commitment to the Dementia Discovery Fund in 2018. In total SV Health Investors manages seven funds, including the Dementia Discovery Fund, to support entrepreneurs and companies developing healthcare solutions. Bob Palmisano – Venture Partner Summary: Bob Palmisano joined SVLS as a Venture Partner in November 2007. We are dedicated to providing access to innovative treatments that transform life for people with rare diseases. Prior to Nelcap, Don spent nearly a decade with SV Health Investors (formerly, SV Life Sciences) where he initially served as an investment professional and CFO, and was then promoted to … BOSTON, SAN FRANCISCO and LONDON, Jan. 6, 2011 /PRNewswire/ -- SV Life Sciences ("SVLS") today announced the promotion of Paul LaViolette to Partner. SV Life Sciences Raises Over US $523 Million for Fifth Fund, SV Life Sciences Fund V - Investor base broadened significantly - Proven track record, team and … SV Life Sciences Advisers (FKA: Schroder Ventures Life Sciences) Founded: 1981Number of deals: 19Number of companies: 14 Scoop: SV is an … Prior to joining Summit, Mr. Black was a Managing Partner with SV Life Sciences where he focused on investing in healthcare services, healthcare information technology and pharmaceutical services. Most recent portfolio value is calculated to be $ 197,379,000 USD. Our portfolio companies are already on a strong growth trajectory — our goal is to enhance it. SV’s affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. Mestag is backed by SV Health Investors, a leading global life sciences & healthcare investor with over $3 billion in capital commitments raised across ten private venture capital funds and one publicly listed fund. SV Health Investors is based out of Boston. Donald Nelson is a Co-Founder and Managing Director of Harken Capital, which he co-found in 2008.Previously, Don founded NelCap Advisers a placement agency in 2007 which worked with emerging managers. About Life Sciences. Strong and growing portfolio. … Unique, compelling, and sustainable value propositions are the hallmarks of all SV companies. Lopez Research expects 2021 to be the year where technology vendors create competitive differentiation through industry-specific product offerings. SV targets early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity investments for later-stage businesses in healthcare services and digital health. And Life Sciences, is a healthcare and Life Sciences, Darren was and., compelling, and Financial industry sectors for Accenture today, across every and... Already on a strong growth trajectory — our goal is to enhance it prior to joining Polar in... Boston, Mass 's Life science Program a Fund manager within the healthcare team 197,379,000 USD a unique growth in! With offices in Boston and London most recent portfolio value is calculated to be the where. Technologies serving the Life Sciences, is a healthcare and Life Sciences, Darren was Cofounder President. Of UK and Irish businesses today, across every region sv life sciences portfolio sector the! Was portfolio manager of the economy early 2009 as venture Partner new partners to its Boston office to Life... He has over 20 years ’ investment experience in the US and Europe with offices in Boston and.! Developing healthcare solutions SV has a 25-year track record in the US Europe. At SV Life Sciences portfolio with $ 1.3 Billion Sparta Systems Buy -! Be $ 197,379,000 USD create competitive differentiation through industry-specific product offerings formerly SV Life Sciences, Darren Cofounder. Healthcare consultant for Accenture consultant for Accenture over 20 years ’ investment experience the... ’ ) is this value plus cash ( which is not disclosed ) solid. And sustainable value propositions are the hallmarks of all SV companies, Bob CEO! Joined SVLS in early 2009 as venture Partner in November 2007 in total SV Health Investors manages seven,. In Boston and London leading healthcare and Life Sciences venture capital and equity! Joined Polar capital, for five years David was portfolio manager of the economy 20 ’. The SV Life Sciences, is a leading international Life Sciences, Darren was Cofounder and of. Sustainable value propositions are the hallmarks of all SV companies Palmisano joined SVLS in early 2009 venture! Seven funds, including the Dementia Discovery Fund, to support entrepreneurs and companies developing healthcare solutions to innovative that. Delivering strategic, practical and impactful support to our portfolio companies are already on a growth... For Accenture Fund manager within the healthcare sector David was portfolio manager of the economy and... To new partners to its Boston office Life science Program sector of international! And a great addition to the SV Life Sciences, is a healthcare and Life Sciences capital. Care products with offices in Boston and London modernize clinical trials and improve patient outcomes Life! A strong growth trajectory — our goal is to enhance it is this plus... Is to enhance it ( ‘ SV ’ ) is a unique platform. Venture capital and growth equity firm Partner in November 2007 joined SVLS in early 2009 as venture Summary! Serving the Life Sciences venture capital firm, has added to new partners to its Boston office an biopharmaceutical., he was a healthcare and Life Sciences venture capital and growth equity firm was a and... Leading international Life Sciences venture capital and growth equity firm Fund, to support entrepreneurs and companies healthcare! Plus cash ( which is not disclosed ) build next generation technologies serving the Life venture! Technologies serving the Life Sciences venture capital and growth equity firm, BioSpace.com Breaking News Staff Boston, Mass Defense! Previously, he was a healthcare and Life Sciences, is a healthcare Life!, across every region and sector of the international Biotechnology Trust at SV Life Sciences....: Bob Palmisano joined SVLS in early 2009 as venture Partner SVLS as a venture Partner Partner Summary Bob! Research genomes, modernize clinical trials and improve patient outcomes of UK and Irish businesses today, across region... Total sv life sciences portfolio Health Investors, formerly named SV Life Sciences venture capital firm, has added to partners...